https://www.biospace.com/article/releases/sound-pharma-advances-pivotal-phase-3-clinical-trials-in-meniere-s-disease/
Sound Pharma advances pivotal Phase 3 clinical trials in Meniere’s Disease
Published: Jun 08, 2020
SEATTLE, June 8, 2020 /PRNewswire/ — Sound Pharmaceuticals is pleased to announce that the FDA has allowed its pivotal Phase 3 clinical protocol for SPI-1005 in the Treatment of Patients with Meniere’s Disease (STOPMD-3).